Parkinson’s Disease Flashcards

MOVEMENT DISORDERS

1
Q

State the Main categories of movement disorders

A
  1. Parkinsonism
    1. slowness of movement/bradykinesia (also a hallmark for diagnosis)
  2. Tremor (can also be symptom)
    1. oscillatory rhythmic movements
  3. Dystonia
    1. torsional patterned movements
  4. 2 AND 3 = EXCESS OF MOVEMENT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

state Parkinson’s disease criteria (PD)

A
  • INSIDIOUS ONSET, SLOWLY PROGRESSING
    • “So slight and nearly imperceptible are the first inroads of this malady, and so extremely slow its progress”
  • UNILATERAL ONSET, BILATERAL PROGRESSION
    • “Thus assuming one of the hands and arms to be first attacked, the other, at this period becomes similarly affected”
  • Motor sumptoms: COMBINATION OF BRADYKINESIA, RIGIDITY AND TREMOR
    • “Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported; with a propensity to bend the trunk forwards”
  • NON-MOTOR SYMPTOMS
    • “the Sleep becomes much disturbed…The Bowels, which had been all along torpid, in most cases, demand stimulating medicines”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

who came up with PD

A

By James Parkinson (1817)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

name a few Risk factors for PD

A

-environmental: increased - prior head injury, decreased - tobacco smoking
-genetics: increased - LRRK2, decreased - SNCA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

name a Neuropathological hallmark of PD:

A

alpha-synuclein aggregation
- Neuronal degeneration of dopaminergic neurons in Substancia Nigra pars compacta
- alpha-synuclein in Lewy bodies - cytoplasmic inclusions
- also found in brainstem, cortex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

describe Braak staging

A
  • 6 neuropathological stages
  • onset in Dorsal Motor X nucleus and olfactory bulb
  • Symptomatic phase when reaching stage 4: midbrain
  • Diffusion to Neocortex in stage 6
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

explain the Literature current controversy:

A
  • a-synuclein - protective aggregation?
    • Is a-synuclein aggregation causative or epiphenomenon of neurodegeneration?
    • Is a-synuclein inhibition of aggregation a correct strategy to slow disease progression?
    • Are other protein aggregates involved? i.e. tau, Beta amyloid?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

name the main disease mechanisms for PD

A

-protein degradation
-mitochondrial function
-synaptic and endosomal vesicle and protein recycling
-inflammation and ageing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cardinal motor signs of PD

A

-asymmetry of clinical signs
-bradykinesia
-rest tremor
-rigidity
-postural instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bradykinesia

A
  • THE CORE FEATURE OF PARKINSONISM
  • Bradykinesia = slowness in movements (reduced speed)
  • Hypokinesia = small amplitude movements (reduced amplitude)
  • Akinesia = absence or poverty of expected spontaneous voluntary movement including slow reaction time (Golbe and Ohman-Strickland, 2007)

> UK BRAIN BANK CRITERIA DEFINITION OF BRADYKINESIA
- Slowness of initiation of voluntary movement with progressive reduction in speed and amplitude of repetitive action = DECREMENT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Rest tremor

A
  • Re-emergent Tremor
  • Rest tremor (rolling pill tremor) is highly suggestive of PD
  • Rest tremor triggered by mental tasks, walking and movements in other body districts
  • Some patients may have postural or action tremor
  • Postural tremor occurs after maintaining a posture for a few seconds (re-emergent tremor)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Rigidity

A

-increased resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Postural instability (later on)

A

can use pull up test to confirm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Gait dysfunction in PD

A
  • LOW Velocity, Cadence, Step length, Arm Swing
  • Asymmetry of stride length
  • Freezing of gait may occur over disease progression
  • Motor blocks when walking: gait initiation, turning, passing through a door
  • running easier vs walking slow for PD patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

PD clinical diagnostic criteria

A

A) Presence of the following cardinal motor signs
- Bradykinesia
- Rest tremor (4-6 Hz): Rolling Pill Tremor
- Rigidity
- Asymmetric Onset

B) Sustained response to Levodopa (medication)

C) Atypical signs exclusions
- Postural instability in the first 3 years
- Early freezing
Early hallucinations and dementia
- Vertical gaze palsy
Marked autonomic system involvement
Secondary causes of parkinsonism (i.e.: neuroleptics, vascular)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Progression of PD: Prodromal phase

A

-50-55
-RBD
-Hyposmia
-anxiety/depression
-constipation

17
Q

what is the heterogenous presentation due to?

A

-disease progression
-disease variability among subtypes

18
Q

Non-motor features and symptoms

A

-pain
-hyposmia
-sleep
-GI
-fatigue
-dysautonomia

19
Q

Factors determining heterogeneity of PD

A
  1. Different combination of cardinal signs e.g. tremor dominant or akinetic rigid
  2. Genotype: presence of a gene variant associated to PD (i.e. GBA mutation
  3. age of presentation (young-onset vs mid-onset vs late onset)
  4. Disease course:
    - Different severity of motor complications
    - Occurrence of axial signs: gait and balance dysfunction, falls
    - Occurrence of different non-motor signs:
    • Sleep impairment
    • Autonomic dysfunction
    • Pain
    • Neuropsychiatric symptoms: anxiety, depression, impulsive-compulsive behaviour, hallucinations, delusions, apathy
    • Cognitive impairment and late-stage
20
Q

PD carriers of a Glucocerebrosidase (GBA) heterozygous variant are more likely to have:

A
  • Akinetic-rigid PD
    • Anxiety
    • Hallucinations
    • Dysautonomia
    • Motor and Non-motor fluctuations
    • Cognitive impairment
21
Q

what’s the difference between young and late onset PD?

A

YOUNG:
-levodopa-induced dyskinesia
-slow motor and cognitive progression
-impulsive-compulsive behaviour
LATE:
-hallucinations
-cognitive impairment
-balance and gait problems
-symptoms poor responsive to L-Dopa

22
Q

Symptomatic treatment of PD

A

no disease modifying treatment
-physical exercise - rehabilitation
-medications
-surgery
-infusions - device aided therapies

23
Q

sites for action of PD action

A

LEVODOPA; increases dopamines
DOPAMINE AGONISTS: mimic dopamine e.g. pramipexole
ANTICHOLINERGIC AGENTS: trihexyphenidyl
BBB: MAO inhibitor e.g. carbidopa

24
Q

dopamine agonists

A

eg. pramipexole D3 >D2
-side effects; sleepiness, leg oedema, impulsive-compulsive behaviour

25
Q

levodopa induced dyskinesia (LID)

A

involuntary choric or choreodystonic movements appearing at the peak of levodopa effect

26
Q

which motor symptoms are mostly due to disease progression

A

-depression/anxiety
-falls
-freezing of gait
-speech disturbance
-postural abnormalities
-apathy

27
Q

which motor symptoms are mostly due to interaction of dopaminergic treatment and disease progression

A

-motor fluctuations
-levodopa-induced dyskinesia

28
Q

which non-motor symptoms are mostly due to interaction of dopaminergic treatment and disease progression

A

-non-motor fluctuations
-impulsive-compulsive
-psychosis
-sleep disorders
-cognitive impairement

29
Q

neuropsychiatric spectrum of PD

A

-affective disorders; depression, anxiety
-psychosis; illusions and hallucinations, delusions
-impulsive-compulsive behaviours (ICB); impulse control disorders, dopamine dysregulation syndrome, punding
-cognitive disturbances; apathy, mild cognitive impairment, dementia

30
Q

Impulsive control disorders (ICD):

A
  • Pathological Gambling
  • Compulsive Shopping
  • Ipersexuality
  • Binge Eating
31
Q

Dopamine Disregulation Syndrome

A

Compulsive use of dopaminergic medication (i.e. levodopa)

32
Q

punding

A

complex prolonged, purposeless, and stereotyped behaviour

33
Q

Risk factors for ICB

A

-young age
- Male gender
- Treatment with
- Dopamine-Agonists

34
Q

Hallucinations

A
  • Minor hallucinations/ Illusions
    • Presence Hallucinations
    • Passage hallucinations
  • Visual Hallucinations
  • Auditory Hallucinations (rare)
  • Hallucinations are triggered by
    Parkinson’s medications.
  • Acute onset of hallucinations often occur in the context of urinary tract infections or any other systemic diseases
35
Q

COGNITIVE IMPAIRMENT AND DEMENTIA

A
  • Cognitive Disturbances in 40% of PD (Cummings, 1988)
  • The full spectrum of cognitive impairment, from subjective cognitive decline to dementia, has been observed in Parkinson disease
  • Mild cognitive impairment in PD usually progresses to dementia, but can be stable and even revert in some patients
  • Time to dementia after PD diagnosis was approximately 10 years
  • Risk factors for dementia in Parkinson by a recent meta-analysis:
    • Older age o Higher motor severity
    • Hallucinations
    • REM sleep behavior disorder
    • Smoking
    • Hypertension
    • Low educational level
36
Q

Novel treatments

A
  • deep brain stimulation
  • levodopa duodenal infusion
  • apomorphine infusion
  • device aided therapies for advanced PD (about 10-20% of patients are eligible)
  • Commercialized devices and stimulating parameters for DBS
    • Amplitude (Volt)
    • Pulse width (mcsec)
    • Frequency (Hz)
    • Active contact:
    • monopolar (case anode)
    • bipolar (case off)
    • Advanced programming
37
Q

deep brain stimulation

A
  • uses electrical stimulation of deep brain structure to treat movement disorders
  • brain pacemaker
  • where to stimulate?
    • Ventralis Intermedius thalamic nucleus (VIM): effective on tremor
    • Globus Pallidus pars interna (Gpi):
      Effective for dykinesia > bradykinesia
    • Nucleo Subtalamico: effective for tremor, bradykinesia, rigidity, non-motor symptoms
38
Q

summarise PD

A
  • Parkinson’s disease is a complex disease, more frequent in older people but it may affect also young people
  • Parkinson’s disease is not only a motor disorders but there is prominent neuropsychiatric involvement as well as presence of many other non-motor symptoms
  • Symptomatic treatment of PD is achieved with a combination of oral medication.
  • Levodopa remains the most effective medication for PD and is combined to IMAOB, ICOMT or dopamine agonists.
  • Device aided therapies can improve quality of life is patients
  • Physical exercise is a symptomatic treatment for PD